ClinicalTrials.gg
CompletedNCT00067743CRPSUpdated Jan 3, 2008

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

A Phase 2 interventional study of Lenalidomide in Complex Regional Pain Syndrome (RSD), sponsored by Celgene Corporation. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2008-01-03.

Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 88 studies in Complex Regional Pain Syndromes with a site in United States — 20 open to participants now, 22 under way, 2 of them phase 3. Complex Regional Pain Syndromes · United States.

Enrollment
24th of 67
40 · median 30
Started
2003
with 1 other
Phase 2
8 of 88
none open now
Registered
3rd of 88
by date

Among the 88 studies in Complex Regional Pain Syndromes with a site in United States, this one is the 24th largest by enrollment of the 67 interventional ones that give a count, is one of 2 that started in 2003, is one of 8 in phase 2, and was the 3rd registered.

Complex Regional Pain Syndromes

206 studies on the registry are indexed under Complex Regional Pain Syndromes; 54 are open to participants now.

Browse Complex Regional Pain Syndromes studies →

Open to participants now

20 of the 88 studies in Complex Regional Pain Syndromes with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 40 Complex Regional Pain Syndromes studies recruiting now, 18 (45%) set no upper age limit and 16 (40%) stop at 75 or younger; 3 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 88 studies in Complex Regional Pain Syndromes with a site in United States, or all of them as a file.
02

Study summary

This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)

Read the detailed description

Once the subject completes the 12 week treatment phase the subject is eligible to continue on the trial. Subjects may continue until no further benefit is obtained.

03

Conditions studied

  • Complex Regional Pain Syndrome (RSD)

Keywords

  • Pain
  • Pain syndrome
  • Reflex sympathetic dystrophy
  • CC-5013
  • CC5013
  • Revlimid
  • Celgene
  • CRPS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A diagnosis of Type 1 CRPS as defined by modified International Association for the Study of Pain criteria (App 1) for at least one year duration
  • Unilateral involvement of a distal hand or foot with or without proximal speed must be present. The most severely affected limb will be designated the index limb.
  • CRPS pain severity score in the index limb of 4 or greater on an 11-point (0-10) NRS (Appendix I).
  • Opioid analgesics, non-opioid analgesics, non-steroidal anti-inflammatory drugs, anticonvulsants and antidepressant drugs may be continued provided that the subject was on stable doses for at least four weeks prior to the Treatment phase.
  • Understand and voluntarily sign an form
  • Able to adhere to the study visit schedule and other protocol requirements
  • Women of (WCBP) must have a negative serum or urine pregnancy test within 7 days of starting study drug.
  • In addition, sexually active WCBP must agree to use adequate methods (oral, injectable, or implantable hormonal contraceptive; tubal ligation; intra-uterine device; barrier contraceptive with spermicide; or vasectomized partner) while on study drug.
  • WCBP must agree to have pregnancy tests every 4 weeks while on study drug.
  • The average CRPS pain severity score in the index limb at the end of the Pre-Treatment Phase I (must be 4 or greater) and 2 each of the daily scores over the week must be within +/- one point of this average.

Exclusion criteria

Exclusion Criteria:

  • Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing the form.
  • Prior treatment with CC-5013
  • Prior development of an allergic reaction/ while taking thalidomide.
  • Prior development of a moderate or sever rash or any desquamation while taking thalidomide.
  • Pregnant or lactating females.
  • Active litigation, compensation or disability issues related to CRPS.
  • Any condition, including the presence of laboratory abnormalities, which places the subject at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.
  • Use of any other experimental drug or therapy within 28 days of the treatment phase.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (actual)

Study arms

  • Other
    1

    Open Label trial

    Drug: Lenalidomide

Interventions

  • supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day

    Also known as: Revlimid

06

What researchers measure

Primary outcomes

  1. Safety

    Time frame: throughout the trial

Secondary outcomes

  1. Change in CRPS pain rating in index limb compared to baseline

    Time frame: throughtout trial compared to baseline

07

Study locations

6 sites
  • UCSD Center for Pain and Palliative Medicine
    La Jolla, California 92093, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • UNC Hospitals University of North Carolina
    Chapel Hill, North Carolina 27599-7010, United States
  • The Center for Clinical Research
    Winston Salem, North Carolina 27103, United States
  • Drexel University College of Medicine
    Philadelphia, Pennsylvania 19102, United States
  • Swedish Pain Management
    Seattle, Washington 98122-4379, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Oct 2004 and a completion of Aug 2007. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 26, 2003
First posted
Aug 27, 2003
Start
Aug 2003
Primary completionActual
Oct 2004
CompletionActual
Aug 2007
Last update
Jan 3, 2008
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 3, 2008, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00067743
First posted
Aug 27, 2003
Start date
Aug 2003
Primary completion
Oct 2004
Completion
Aug 2007
Last update
Jan 3, 2008

Study contacts

Donald Manning, MD, PhD
study director · Celgene Corporation

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2006. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lenalidomide

Start the discussion